NCLS: 530/351.000; 435/194.000 * * * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * IC ICM: C07K014-705 435/194; 530/350; 530/351 ... EXF FILE 'HOME' ENTERED ON 23 NOV 1998 ANSWER 3 OF 405 USPATFULL L1=> file uspatfull 1998:144212 USPATFULL ΑN Interleukin-2 receptor subunit ΤI => s ((tumor? necros? factor?) or ectodomain fusion protein tnf?)(5a)receptor? comprising a leucine zipper domain Ciardelli, Thomas L., Sharon, VT, . 24416 TUMOR? United States 7979 NECROS? Johnson, Kirk, Moraga, CA, United 432703 FACTOR? 2469 TUMOR? NECROS? FACTOR? States Chiron Corporation, Emeryville, CA, (TUMOR? (W) NECROS? (W) FACTOR?) PA United States (U.S. 2875 TNF? corporation) 35182 RECEPTOR? Trustee of Dartmouth College, Hanover, 405 ((TUMOR? NECROS? FACTOR?) OR NH, United States (U.S. TNF?) (5A) RECEPTOR? corporation) US 5837816 981117 ΡI => d 1-20US 95-474741 950607 (8) AΤ Continuation-in-part of Ser. No. US RLI 95-438259, filed on 10 May ANSWER 1 OF 405 USPATFULL 1995, now abandoned 1998:144233 USPATFULL Utility 'nТ Nucleic acids molecules encoding LN.CNT 1970 Caspase-8h and Caspase-8i INCLM: 530/350.000 Hunter, John J., Cambridge, MA, United INCL TN INCLS: 435/069.100; 435/320.100; States 536/023.400; 536/024.100; Shyjan, Andrew W., Nahant, MA, United 514/002,000 States NCLM: 530/350.000 NCLS: 435/069.100; 435/320.100; Wong, Grace H. W., Brookline, MA, NCL United States 536/023.400; 536/024.100; Millennium Pharmaceuticals, Inc., 514/002.000 Cambridge, MA, United States (U.S. corporation) ICM: C07K014-435 US 5837837 981117 PΙ ICS: C07K014-705; C07K014-715; US 97-807200 970227 (8) AΙ C12N015-12 Utility DΤ 530/350; 435/69.1; 435/320.1; EXF LN.CNT 2079 435/240.2; 435/325; 435/7.1; INCLM: 536/023.100 INCL 536/23.4; 514/2 INCLS: 530/300.000; 530/350.000 CAS INDEXING IS AVAILABLE FOR THIS PATENT. NCLM: 536/023.100 NCL NCLS: 530/300.000; 530/350.000 1.1 ANSWER 4 OF 405 USPATFULL IC [6] 1998:144102 USPATFULL AN ICM: C07H021-02 Amino-alcohol substituted cyclic ICS: A61K038-00; C07K001-00 ΤI compounds 536/23.1; 530/350; 435/172.3; Kumar, Anil M., Seattle, WA, United TN 435/69.1; 435/325; 424/93.2 CAS INDEXING IS AVAILABLE FOR THIS PATENT. States Michnick, John, Seattle, WA, United States ANSWER 2 OF 405 USPATFULL 1.1 Underiner, Gail E., Brier, WA, United 1998:144213 USPATFULL ΑN States Tumor necrosis factor Klein, J. Peter, Vashon Island, WA, receptor-II-associated protein kinase United States and methods for its Rice, Glenn C., Seattle, WA, United use States Aggarwal, Bharat B., Houston, TX, ΤN Cell Therapeutics, Inc., Seattle, WA, PA United States Darnay, Bryant G., Houston, TX, United United States (U.S. corporation) US 5837703 981117 PΙ Research Development Foundation, PA US 93-152650 931112 (8) ΑI Carson City, NV, United States (U.S. corporation) Continuation-in-part of Ser. No. US RLI 93-40820, filed on 31 Mar US 5837817 981117 1993, now abandoned US 96-588604 960118 (8) ΑI Utility Continuation-in-part of Ser. No. US RLI LN.CNT 2596 94-272005, filed on 7 Jul INCLM: 514/183.000 1994, now abandoned INCLS: 514/211.000; 514/228.800; Utility 514/241.000; 514/242.000; LN.CNT 953 514/249.000; 514/256.000; INCLM: 530/350.000 INCL 514/259.000; 514/263.000; INCLS: 530/351.000; 435/194.000 514/270.000; 514/274.000;

514/309.000; 514/312.000;

NCL

NCLM: 530/350.000

US 96-583276 960105 (8) ΑI 514/315.000; 514/348.000; Continuation of Ser. No. US 94-332444, RLI 514/357.000; 514/374.000; filed on 31 Oct 1994, now 514/400.000; 514/425.000; abandoned which is a continuation of 514/427.000; 540/467.000; Ser. No. US 92-887712, filed 540/544.000; 544/216.000; on 22 May 1992, now abandoned 544/257.000; 544/272.000; DT Utility 544/286.000; 544/301.000; LN.CNT 1231 544/311.000; 544/335.000; INCLM: 435/325.000 INCL 546/096.000; 546/141.000; INCLS: 536/023.500; 435/069.100; 546/142.000; 546/157.000; 435/320,100 546/246.000; 546/296.000; 435/325.000 NCL NCLM: 546/334.000; 548/215.000; NCLs: 536/023.500; 435/069.100; 548/340.100; 548/485.000; 435/320.100 548/546.000; 548/561.000 IC 161 514/183.000 NCLM: ICM: C12N005-22 514/211.000; 514/228.800; NCLS: ICS: C12N015-12; C12N015-86 514/241.000; 514/242.000; 536/23.1; 435/69.1; 435/320.1; EXF 514/249.000; 514/256.000; 435/240.2; 435/325 514/259.000; 514/263.000; 514/270.000; 514/274.000; ANSWER 6 OF 405 USPATFULL 1.1 514/309.000; 514/312.000; 1998:143904 USPATFULL AΝ 514/315.000; 514/348.000; Directed evolution of novel binding ΤI 514/357.000; 514/374.000; proteins 514/400.000; 514/425.000; Ladner, Robert Charles, Ijamsville, IN 514/427.000; 540/467.000; MD, United States 540/544.000; 544/216.000; Gutterman, Sonia Kosow, Belmont, MA, 544/257.000; 544/272.000; United States 544/286.000; 544/301.000; Roberts, Bruce Lindsay, Milford, MA, 544/311.000; 544/335.000; 546/096.000; 546/141.000; United States Markland, William, Milford, MA, United 546/142.000; 546/157.000; States 546/246.000; 546/296.000; Ley, Arthur Charles, Newton, MA, 546/334.000; 548/215.000; United States 548/340.100; 548/485.000; Kent, Rachel Baribault, Boxborough, 548/546.000; 548/561.000 MA, United States PA Dyax, Corp., Cambridge, MA, United States (U.S. corporation) [6] ICM: A61K031-55 ICS: A61K031-515; A61K031-445; US 5837500 981117 A61K031-52 US 95-415922 950403 (8) 544/276; 544/272; 544/216; 544/257; ΑI Continuation of Ser. No. US 93-9319, RLT 544/285; 544/286; 544/301; filed on 26 Jan 1993, now 544/311; 544/335; 514/263; 514/183; patented, Pat. No. US 5403484 which is 514/211; 514/228.8; 514/241; a division of Ser. No. US 514/242; 514/249; 514/256; 514/259; 91-664989, filed on 1 Mar 1991, now 514/270; 514/274; 514/309; patented, Pat. No. US 5223409 514/312; 514/315; 514/348; 514/357; which is a continuation-in-part of 514/374; 514/400; 514/418; Ser. No. US 90-487063, filed on 514/425; 514/427; 540/467; 540/544; 2 Mar 1990, now abandoned which is a 546/96; 546/141; 546/142; continuation-in-part of Ser. 546/157; 546/246; 546/296; 546/334; No. US 88-240160, filed on 2 Sep 1988, 548/215; 548/340.1; 548/485; now abandoned 548/546; 548/561 CAS INDEXING IS AVAILABLE FOR THIS PATENT. DT Utility LN.CNT 15973 INCLM: 435/069.700 INCL ANSWER 5 OF 405 USPATFULL INCLS: 435/172.300; 530/350.000; 1998:143939 USPATFULL AN 530/412.000; 536/023.400 Expression of human multidrug ΤI NCLM: 435/069.700 NCL resistance genes and improved 435/172.300; 530/350.000; NCLS: selection of cells transduced with 530/412.000; 536/023.400 [6] McDonagh, Kevin T., Silver Spring, MD, TN ICM: C12N015-62 United States ICS: C07K019-00 Nienhuis, Arthur, Bethesda, MD, United 435/69.7; 435/172.3; 530/350; 530/412; EXF States 536/23.4 Tolstoshev, Paul, Potomac, MD, United States ANSWER 7 OF 405 USPATFULL Genetic Therapy, Inc., Gaithersburg, 1.1 1998:143875 USPATFULL ΑN MD, United States (U.S. Method of recovering a biological ΤI corporation) molecule from a recombinant The United States of America as microorganism represented by the Department of Carlson, Peter S., Alexandria, VA, Health and Human Services, Washington, United States DC, United States (U.S. Quintero, Ernesto J., McLean, VA, government) United States US 5837536 981117

,

US 5834485 981110 Manyak, David M., Ellicott City, MD, PΤ AI US 97-858969 970520 (8) PRAI GB 96-10506 960520 United States Chmurny, Alan B., Frederick, MD, United States GB 96-23234 961107 GB 96-26883 961224 Oceanix Biosciences Corporation, GB 97-8071 970422 Hanover, MD, United States (U.S. Utility corporation) DΤ US 5837470 981117 US 98-21984 980211 LN.CNT 732 INCLM: 514/311.000 ΑT INCL Division of Ser. No. US 96-766308, RLI INCLS: 514/312.000; 514/313.000; filed on 13 Dec 1996 514/314.000; 546/153.000; 546/155.000; 546/156.000; Utility LN.CNT 1493 546/157.000; 546/159.000; INCL INCLM: 435/006.000 546/160.000; 546/168.000; INCLS: 435/069.100; 435/172.300; 546/169.000; 546/170.000; 435/172.200; 435/252.300 546/172.000 NCLM: 435/006.000 NCLS: 435/069.100; 435/172.300; NCL NCLM: 514/311.000 NCLS: 514/312.000; 514/313.000; 435/172.200; 435/252.300 514/314.000; 546/153.000; [6] 546/155.000; 546/156.000; ICM: C12Q001-68 546/157.000; 546/159.000; ICS: C12P021-02 546/160.000; 546/168.000; EXF 435/6; 435/69.1; 435/172.2; 435/172.3; 546/169.000; 546/170.000; 435/252.3 546/172.000 IC ANSWER 8 OF 405 USPATFULL 1.1 ICM: C07D215-36 1998:139020 USPATFULL AN ICS: A61K031-47 ΤT Chimeric viral receptor polypeptides EXF 546/154; 546/155; 546/156; 546/157; IN Meruelo, Daniel, Scarborough, NY, 546/160; 546/162; 546/172; 514/311; 514/312; 514/313; 514/314 Yoshimoto, Takayuki, Tokyo, Japan New York University, New York, NY, L1 ANSWER 10 OF 405 USPATFULL United States (U.S. AN 1998:138868 USPATFULL corporation) TΙ Inhibition of TNF-.alpha. pleiotropic PΙ US 5834589 981110 and cytotoxic effects US 93-132990 931007 (8) AΤ IN Slesarev, Vladimir I., 20 Colebrook Continuation-in-part of Ser. No. US La., Conroe, TX, United States 93-84729, filed on 29 Jun 77304 1993, now abandoned which is a PΙ US 5834435 981110 US 96-757477 961127 (8) continuation-in-part of Ser. No. US ΑI 92-899075, filed on 11 Jun 1992, now Utility DT abandoned which is a LN.CNT 611 continuation-in-part of Ser. No. US INCL INCLM: 514/019.000 91-806178, filed on 13 Dec INCLS: 514/008.000; 514/016.000; 514/921.000; 514/885.000; 1991, now abandoned which is a continuation-in-part of Ser. No. US 530/322.000 90-627950, filed on 14 Dec 1990, now NCLM: 514/019.000 NCLS: 514/008.000; 514/016.000; NCL abandoned Utility 514/921.000; 514/885.000; LN.CNT 3800 530/322.000 INCLM: 530/350.000 INCL INCLS: 530/387.300; 530/388.300; ICM: A61K038-05 530/389.100; 530/826.000; EXF 514/19; 514/8; 514/16; 514/921; 435/171.300 514/885; 530/322 NCLM: 530/350.000 NCLS: 530/387.300; 530/388.300; NCL. 1.1 ANSWER 11 OF 405 USPATFULL 530/389.100; 530/826.000; AN 1998:138853 USPATFULL 435/171.300 TΤ Chemokine binding protein and methods IC of use therefor ICM: C12N015-00 IN McFadden, Grant, Edmonton, Canada ICS: C12P021-08; C07K016-00; C07K014-Lucas, Alexandra, Edmonton, Canada 0.0 PA The John P. Robarts Institute, London, EXF 530/350; 530/387.3; 530/387.1; Canada (non-U.S. 530/387.7 corporation) PΤ US 5834419 981110 L1 ANSWER 9 OF 405 USPATFULL ΑI US 96-634924 960419 (8) ΔN 1998:138917 USPATFULL Continuation-in-part of Ser. No. US RLI Quinoline sulfonamides and their 95-424850, filed on 19 Apr therapeutic use 1995, now abandoned Dyke, Hazel Joan, Cambridge, United Utility LN.CNT 1033 Montana, John Gary, Cambridge, United INCL INCLM: 514/002.000 INCLS: 514/008.000; 514/012.000; PA Chiroscience Limited, United Kingdom 530/350.000; 424/084.000 (non-U.S. corporation) NCL NCLM: 514/002.000

NCLS: 514/008.000; 514/012.000; RLT Continuation of Ser. No. US 95-483039, 530/350.000; 424/084.000 filed on 6 Jun 1995, now patented, Pat. No. US 5766854 which is TC 161 ICM: C61K038-16 a continuation of Ser. No. ICS: C07K014-065 US 94-190723, filed on 2 Feb 1994, now 530/350; 514/2; 514/8; 514/12; 424/84 patented, Pat. No. US EXF 5580723 which is a continuation of ANSWER 12 OF 405 USPATFULL Ser. No. US 92-960227, filed on Ll 1998:138709 USPATFULL 13 Oct 1992, now abandoned which is a continuation of Ser. No. US Regulated apoptosis TΙ Crabtree, Gerald R., Woodside, CA, 92-875204, filed on 27 Apr 1992, now TN abandoned which is a United States Schreiber, Stuart L., Cambridge, MA, continuation of Ser. No. US 89-428066, United States filed on 26 Oct 1989, now abandoned which is a continuation-in-Spencer, David M., Los Altos, CA, United States part of Ser. No. US 88-264611, filed on 28 Oct 1988, now Wandless, Thomas J., Cambridge, MA, United States abandoned Belshaw, Peter, Somerville, MA, United DТ Utility LN.CNT 3240 President & Fellows of Harvard INCL INCLM: 435/007.100 PA College, Cambridge, MA, United INCLS: 435/004.000; 435/006.000; 436/501.000; 530/300.000; States (U.S. corporation) Board of Trustees of Leland Stanford 530/326.000 NCLM: 435/007.100 Jr. University, Stanford, CA, United States (U.S. corporation) NCLS: 435/004.000; 435/006.000; US 5834266 981110 436/501.000; 530/300.000; US 94-292597 940818 (8) 530/326.000 ΑI Continuation-in-part of Ser. No. US [6] RLT ICM: G01N033-53 94-179143, filed on 7 Jan 1994, now abandoned And Ser. No. US ICS: G01N033-566 EXF 435/7.1; 435/4; 435/6; 435/69.1; 94-179748, filed on 7 Jan 1994 435/71.1; 436/501; 530/300; which is a continuation-in-part of Ser. No. US 93-92977, filed on 530/326; 530/350; 530/387.1; 16 Jul 1993, now abandoned which is a 530/388.1; 530/399; 530/806; 530/808 continuation-in-part of Ser. No. US 93-17931, filed on 12 Feb 1993, ANSWER 14 OF 405 USPATFULL L1 1998:138593 USPATFULL now abandoned , said Ser. AN No. US -179143 which is a TТ Composition of photoconductive layer for a color display panel
IN Kim, Min Ho, Suwon-si, Korea, Republic continuation-in-part of Ser. No. US 93-93499, filed on 16 Jul 1993 DΤ Utility of LN.CNT 5242 Park, Wan Woo, Suwon-si, Korea, INCL INCLM: 435/172.300 Republic of INCLS: 435/320.100; 435/325.000; Samsung Display Devices Co., Ltd., PΑ 435/366.000; 536/234.000 Suwon-si, Korea, Republic of NCL NCLM: 435/172.300 NCLS: 435/320.100; 435/325.000; 435/366.000; 536/234.000 (non-U.S. corporation) ΡI US 5834144 981110 US 97-935443 970923 (8) AΙ PRAI KR 96-61603 961204 [6] ICM: C12N015-62 KR 96-61606 961204 ICS: C12N015-63; C12N015-79; C12N005-Utility LN.CNT 378 10 424/93.21; 514/44; 435/69.7; INCL INCLM: 430/028.000 435/240.2; 435/320.1; 435/23.4; NCL NCLM: 430/028.000 435/23.5; 435/325; 435/366; 435/372.3; IC [6] ICM: G03C005-00 435/172.3; 536/23.4; 536/23.5 EXF 430/28; 430/58; 430/59 CAS INDEXING IS AVAILABLE FOR THIS PATENT. ANSWER 15 OF 405 USPATFULL 1.1 ANSWER 13 OF 405 USPATFULL AN 1998:135173 USPATFULL L1 1998:138693 USPATFULL ΤI Interleukin-8 anti-peptide antibodies Method for identifying active domains TI IN Schraufstatter, Ingrid U., San Diego, and amino acid residues in CA. United States polypeptides and hormone variants Cochrane, Charles G., La Jolla, CA, Wells, James A., Burlingame, CA, United States The Scripps Research Institute, La United States PA Jolla, CA, United States (U.S. Cunningham, Brian C., Piedmont, CA, United States corporation) US 5831032 981103 US 96-643515 960506 (8) Genentech, Inc., South San Francisco, PΙ CA, United States (U.S. ΑI corporation) RLI Division of Ser. No. US 94-342348, filed on 21 Nov 1994, now US 5834250 981110 ΑI US 97-903398 970630 (8) abandoned which is a continuation of Ser. No. US 91-755824, filed

on 6 Sep 1991, now abandoned which is 435/069.700 NCLM: 514/012.000 a continuation-in-part of NCL Ser. No. US 90-581673, filed on 12 Sep NCLS: 514/013.000; 514/014.000; 1990, now abandoned 514/015.000; 514/021.000; Utility 435/069.700 LN.CNT 1372 TC [6] INCLM: 530/387.900 INCL ICM: A61K038-08 INCLS: 530/388.100; 530/388.230; ICS: A61K038-10; A61K038-17 530/389.200; 530/326.000; EXF 514/12; 514/13; 514/14; 514/15; 530/412.000; 530/413.000 514/21; 435/69.7 NCLM: 530/387.900 NCLS: 530/388.100; 530/388.230; NCL CAS INDEXING IS AVAILABLE FOR THIS PATENT. 530/389.200; 530/326.000; ANSWER 18 OF 405 USPATFULL 530/412.000; 530/413.000 AN 1998:134631 USPATFULL [6] TΙ Fas antagonists and uses thereof ICM: C07K016-24 Lynch, David H., Bainbridge Island, IN EXF 560/387.1; 560/388.1; 560/388.25; United States WA, 560/389.2; 560/387.9; 560/326; Alderson, Mark R., Bainbridge Island, 514/412; 514/413 WA, United States PA Immunex Corporation, Seattle, WA, ANSWER 16 OF 405 USPATFULL 1.1 United States (U.S. corporation) AN 1998:135151 USPATFULL PΙ US 5830469 981103 TI Human receptor for interleukin-12 ΑI US 95-429499 950426 (8) Chua, Anne On, Wayne, NJ, United IN RLT Continuation-in-part of Ser. No. US States 94-322805, filed on 13 Oct Gubler, Ulrich Andreas, Glen Ridge, 1994, now patented, Pat. No. US NJ, United States 5620889 which is a PΑ Hoffmann-La Roche Inc., Nutley, NJ, continuation-in-part of Ser. No. US United States (U.S. 93-159003, filed on 29 Nov corporation) 1993, now abandoned which is a continuation-in-part of Ser. No. US US 5831007 981103 US 95-419652 950411 (8) ΑT 93-136817, filed on 14 Oct 1993, now Division of Ser. No. US 94-248532, RLI abandonedfiled on 31 May 1994, now DT Utility patented, Pat. No. US 5536657 which is LN.CNT 1993 a continuation-in-part of INCL INCLM: 424/144.100 Ser. No. US 93-94713, filed on 19 Jul INCLS: 424/143.100; 424/153.100; 1993, now abandoned 424/154.100; 424/155.100; Utility 424/156.100; 530/388.200; LN.CNT 1929 530/388.220; 530/388.230; INCL INCLM: 530/350.000 530/388.240; 435/332.000 INCLS: 530/351.000; 514/002.000; NCL NCLM: 424/144.100 514/008.000 NCLS: 424/143.100; 424/153.100; NCLM: 530/350.000 NCL. 424/154.100; 424/155.100; NCLS: 530/351.000; 514/002.000; 424/156.100; 530/388.200; 514/008.000 530/388.220; 530/388.230; IC 161 530/388.240; 435/332.000 ICM: C07K014-715 IC EXF 514/2; 514/8; 530/350; 530/351 ICM: A16K039-395 ICS: A16K035-12; C07K016-18; C12N005-ANSWER 17 OF 405 USPATFULL 12 1998:135009 USPATFULL AN EXF 424/141.1; 424/154.1; 424/143.1; TΤ Peptides with bactericidal activity 424/140.1; 424/144.1; 424/155.1; and endotoxin neutralizing 424/156.1; 424/153.1; 530/388.1; activity for gram negative bacteria 530/387.1; 530/388.73; and methods for their use 530/388.75; 530/388.2; 530/388.22; Gray, Beulah H., St. Paul, MN, United 530/388.23; 530/388.24; 435/332 States Haseman, Judith R., Eagan, MN, United ANSWER 19 OF 405 USPATFULL AN 1998:134626 USPATFULL Mayo, Kevin H., Minnetonka, MN, United TΤ Regulated transcription of targeted States genes and other biological PA Regents of the University of events Minnesota, Minneapolis, MN, United Crabtree, Gerald R., Woodside, CA, IN States (U.S. corporation) United States US 5830860 981103 PΙ Schreiber, Stuart L., Cambridge, MA, US 96-653632 960524 (8) ΑI United States Continuation-in-part of Ser. No. US RLI Spencer, David M., Los Altos, CA, 94-218026, filed on 24 Mar United States 1994 Wandless, Thomas J., Cambridge, MA, DΤ Utility United States LN.CNT 3083 Belshaw, Peter, Cambridge, MA, United INCL INCLM: 514/012.000 States INCLS: 514/013.000; 514/014.000; President & Fellows of Harvard PA 514/015.000; 514/021.000; College, Cambridge, MA, United

L2 292 L1 AND (CLON? OR CDNA?) States (U.S. corporation) Board of Trustees of Leland S. Stanford, Jr. University, Stanford, => d 1-20CA, United States (U.S. corporation) US 5830462 981103 L2 ANSWER 1 OF 292 USPATFULL US 95-478386 950607 (8) ΑI AN 1998:144233 USPATFULL
TI Nucleic acids molecules encoding Division of Ser. No. US 95-388653, RLI filed on 14 Feb 1995 And a continuation-in-part of Ser. No. US Caspase-8h and Caspase-8i Hunter, John J., Cambridge, MA, United 94-292597, filed on 18 Aug TN 1994 which is a continuation-in-part States Shyjan, Andrew W., Nahant, MA, United of Ser. No. US 94-179748, filed on 7 Jan 1994, now abandoned which is a continuation-in-part Wong, Grace H. W., Brookline, MA, United States of Ser. No. US 93-92977, filed on 16 Jul 1993, now abandoned which PA Millennium Pharmaceuticals, Inc., Cambridge, MA, United States is a continuation-in-part of Ser. No. US 93-17931, filed on 12 Feb 1993, now abandoned , said Ser. No. US (U.S. corporation) US 5837837 981117 ΡT -388653 which is a US 97-807200 970227 (8) ΑT Utility continuation-in-part of Ser. No. US DT 94-196043, filed on 11 Feb LN.CNT 2079 INCL INCLM: 536/023.100 1994 which is a continuation-in-part of Ser. No. US -179748 INCLS: 530/300.000; 530/350.000 which is a continuation-in-part of NCLM: 536/023.100 NCL Ser. No. US -92977 which is a NCLS: 530/300.000; 530/350.000 continuation-in-part of Ser. No. US IC [6] ICM: C07H021-02 Utility ICS: A61K038-00; C07K001-00 DT LN.CNT 4524 536/23.1; 530/350; 435/172.3; EXF INCLM: 424/093.210 435/69.1; 435/325; 424/93.2 INCLS: 435/172.300; 514/044.000 CAS INDEXING IS AVAILABLE FOR THIS PATENT. NCLM: 424/093.210 NCLS: 435/172.300; 514/044.000 NCL 1.2 ANSWER 2 OF 292 USPATFULL 1998:144213 USPATFULL AN [6] ICM: C12N015-63 Tumor necrosis factor ICS: A61K031-70; A61K048-00 receptor-II-associated protein kinase 435/69.1; 435/69.7; 435/240.2; and methods for its 435/320.1; 435/172.3; 935/34; use 935/36; 935/70; 935/71; 424/93.21; IN Aggarwal, Bharat B., Houston, TX, 514/44 United States Darnay, Bryant G., Houston, TX, United ANSWER 20 OF 405 USPATFULL States L1 1998:134612 USPATFULL ΑN PA Research Development Foundation, Carson City, NV, United States (U.S. corporation) Compositions and methods for the TΙ treatment of tumors US 5837817 981117 IN Vehar, Gordon A., San Carlos, CA, United States US 96-588604 960118 (8) ΑT RLI PA Genentech, Inc., South San Francisco, Continuation-in-part of Ser. No. US CA, United States (U.S. 94-272005, filed on 7 Jul corporation) 1994, now abandoned PΤ US 5830448 981103 Utility US 95-470777 950606 (8) LN.CNT 953 Division of Ser. No. US 94-260850, INCL INCLM: 530/350.000 filed on 16 Jun 1994 INCLS: 530/351.000; 435/194.000 DТ Utility NCL NCLM: 530/350.000 LN.CNT 1698 NCLS: 530/351.000; 435/194.000 INCL INCLM: 424/085.200 IC [6] INCLS: 514/002.000; 530/351.000; ICM: C07K014-705 530/381.000; 424/085.500; EXF 435/194; 530/350; 530/351 424/085.100 NCLM: 424/085.200 NCLS: 514/002.000; 530/351.000; L2 ANSWER 3 OF 292 USPATFULL AN 1998:144212 USPATFULL 530/381.000; 424/085.500; Interleukin-2 receptor subunit TI 424/085.100 ectodomain fusion protein comprising a leucine zipper domain ICM: A61K045-05 Ciardelli, Thomas L., Sharon, VT, ICS: A61K038-00 United States 514/2; 530/351; 530/381; 424/85.2; Johnson, Kirk, Moraga, CA, United 424/85.5; 424/85.1 States Chiron Corporation, Emeryville, CA, => s ll and (clon? or cdna?) United States (U.S. corporation)

23616 CLON? 10407 CDNA?

Trustee of Dartmouth College, Hanover, 514/249.000; 514/256.000; 514/259.000; 514/263.000; NH, United States (U.S. 514/270.000; 514/274.000; corporation) PΙ US 5837816 981117. 514/309.000; 514/312.000; US 95-474741 950607 (8) 514/315.000; 514/348.000; Continuation-in-part of Ser. No. US 514/357.000; 514/374.000; RLI 514/400.000; 514/425.000; 95-438259, filed on 10 May 514/427.000; 540/467.000; 1995, now abandoned Utility 540/544.000; 544/216.000; LN.CNT 1970 544/257.000; 544/272.000; 544/286.000; 544/301.000; INCL INCLM: 530/350.000 INCLS: 435/069.100; 435/320.100; 544/311.000; 544/335.000; 536/023.400; 536/024.100; 546/096.000; 546/141.000; 514/002.000 546/142.000; 546/157.000; NCLM: 530/350.000 546/246.000; 546/296.000; NCLS: 435/069.100; 435/320.100; 546/334.000; 548/215.000; 548/340.100; 548/485.000; 536/023.400; 536/024.100; 514/002.000 548/546.000; 548/561.000 [6] IC [6] ICM: C07K014-435 ICM: A61K031-55 ICS: C07K014-705; C07K014-715; ICS: A61K031-515; A61K031-445; A61K031-52 C12N015-12 530/350; 435/69.1; 435/320.1; 544/276; 544/272; 544/216; 544/257; EXF EXF 435/240.2; 435/325; 435/7.1; 544/285; 544/286; 544/301; 536/23.4; 514/2 544/311; 544/335; 514/263; 514/183; CAS INDEXING IS AVAILABLE FOR THIS PATENT. 514/211; 514/228.8; 514/241; 514/242; 514/249; 514/256; 514/259; 514/270; 514/274; 514/309; ANSWER 4 OF 292 USPATFULL L2 1998:144102 USPATFULL 514/312; 514/315; 514/348; 514/357; AN TΙ Amino-alcohol substituted cyclic 514/374; 514/400; 514/418; 514/425; 514/427; 540/467; 540/544; compounds 546/96; 546/141; 546/142; 546/157; 546/246; 546/296; 546/334; ΤN Kumar, Anil M., Seattle, WA, United States Michnick, John, Seattle, WA, United 548/215; 548/340.1; 548/485; 548/546; 548/561 States CAS INDEXING IS AVAILABLE FOR THIS PATENT. Underiner, Gail E., Brier, WA, United States ANSWER 5 OF 292 USPATFULL Klein, J. Peter, Vashon Island, WA, L2 1998:143939 USPATFULL United States Rice, Glenn C., Seattle, WA, United TΙ Expression of human multidrug States resistance genes and improved Cell Therapeutics, Inc., Seattle, WA, selection of cells transduced with United States (U.S. such denes corporation) IN McDonagh, Kevin T., Silver Spring, MD, PΙ US 5837703 981117 United States US 93-152650 931112 (8) Nienhuis, Arthur, Bethesda, MD, United Continuation-in-part of Ser. No. US States 93-40820, filed on 31 Mar Tolstoshev, Paul, Potomac, MD, United 1993, now abandoned States Utility PΑ Genetic Therapy, Inc., Gaithersburg, LN.CNT 2596 MD. United States (U.S. INCLM: 514/183.000 corporation) INCL INCLS: 514/211.000; 514/228.800; The United States of America as 514/241.000; 514/242.000; represented by the Department of 514/249.000; 514/256.000; Health and Human Services, Washington, 514/259.000; 514/263.000; DC, United States (U.S. 514/270.000; 514/274.000; government) 514/309.000; 514/312.000; US 5837536 981117 US 96-583276 960105 (8) 514/315.000; 514/348.000; AΤ 514/357.000; 514/374.000; RLI Continuation of Ser. No. US 94-332444, 514/400.000; 514/425.000; filed on 31 Oct 1994, now 514/427.000; 540/467.000; abandoned which is a continuation of 540/544.000; 544/216.000; Ser. No. US 92-887712, filed 544/257.000; 544/272.000; on 22 May 1992, now abandoned 544/286.000; 544/301.000; Utility LN.CNT 1231 544/311.000; 544/335.000; 546/096.000; 546/141.000; INCL INCLM: 435/325.000 INCLS: 536/023.500; 435/069.100; 546/142.000; 546/157.000; 546/246.000; 546/296.000; 435/320.100 NCLM: 546/334.000; 548/215.000; NCL 435/325.000 548/340.100; 548/485.000; 536/023.500; 435/069.100; NCLS: 548/546.000; 548/561.000 435/320.100 NCLM: 514/183.000 NCLS: 514/211.000; 514/228.800; IC [6] ICM: C12N005-22 514/241.000; 514/242.000; ICS: C12N015-12; C12N015-86

536/23.1; 435/69.1; 435/320.1; NCLS: 435/069.100; 435/172.300; 435/172.200; 435/252.300 435/240.2; 435/325 IC [6] ANSWER 6 OF 292 USPATFULL ICM: C12Q001-68 1998:143904 USPATFULL ΑN ICS: C12P021-02 Directed evolution of novel binding TΤ EXF 435/6; 435/69.1; 435/172.2; 435/172.3; proteins 435/252.3 TN Ladner, Robert Charles, Ijamsville, MD, United States L2 ANSWER 8 OF 292 USPATFULL Gutterman, Sonia Kosow, Belmont, MA, AN 1998:139020 USPATFULL United States ጥፐ Chimeric viral receptor polypeptides Roberts, Bruce Lindsay, Milford, MA, IN Meruelo, Daniel, Scarborough, NY, United States United States Markland, William, Milford, MA, United Yoshimoto, Takayuki, Tokyo, Japan New York University, New York, NY, PA Ley, Arthur Charles, Newton, MA, United States (U.S. United States corporation) Kent, Rachel Baribault, Boxborough, PΙ US 5834589 981110 MA, United States ΑI US 93-132990 931007 (8) Dyax, Corp., Cambridge, MA, United RLI Continuation-in-part of Ser. No. US States (U.S. corporation) 93-84729, filed on 29 Jun US 5837500 981117 1993, now abandoned which is a US 95-415922 950403 (8) ΑT continuation-in-part of Ser. No. US RLI Continuation of Ser. No. US 93-9319, 92-899075, filed on 11 Jun 1992, now filed on 26 Jan 1993, now abandoned which is a patented, Pat. No. US 5403484 which is continuation-in-part of Ser. No. US a division of Ser. No. US $\,$ 91-806178, filed on 13 Dec 91-664989, filed on 1 Mar 1991, now 1991, now abandoned which is a patented, Pat. No. US 5223409 continuation-in-part of Ser. No. US which is a continuation-in-part of 90-627950, filed on 14 Dec 1990, now Ser. No. US 90-487063, filed on abandoned 2 Mar 1990, now abandoned which is a Utility DT LN.CNT 3800 continuation-in-part of Ser. No. US 88-240160, filed on 2 Sep 1988, INCL INCLM: 530/350.000 now abandoned INCLS: 530/387.300; 530/388.300; Utility 530/389.100; 530/826.000; LN.CNT 15973 435/171.300 INCL INCLM: 435/069.700 NCLM: 530/350.000 INCLS: 435/172.300; 530/350.000; NCLS: 530/387.300; 530/388.300; 530/412.000; 536/023.400 530/389.100; 530/826.000; NCLM: 435/069.700 NCLS: 435/172.300; 530/350.000; 435/171.300 IC [6] 530/412.000; 536/023.400 ICM: C12N015-00 [6] ICS: C12P021-08; C07K016-00; C07K014-ICM: C12N015-62 ICS: C07K019-00 EXF 530/350; 530/387.3; 530/387.1; EXF 435/69.7; 435/172.3; 530/350; 530/412; 530/387.7 L2 ANSWER 9 OF 292 USPATFULL ANSWER 7 OF 292 USPATFULL AN 1998:138853 USPATFULL 1998:143875 USPATFULL TΙ Chemokine binding protein and methods Method of recovering a biological of use therefor molecule from a recombinant IN McFadden, Grant, Edmonton, Canada microorganism Lucas, Alexandra, Edmonton, Canada Carlson, Peter S., Alexandria, VA, PΑ The John P. Robarts Institute, London, United States Canada (non-U.S. Quintero, Ernesto J., McLean, VA, corporation) United States PΤ US 5834419 981110 Manyak, David M., Ellicott City, MD, US 96-634924 960419 (8) ΑI United States RLI Continuation-in-part of Ser. No. US Chmurny, Alan B., Frederick, MD, 95-424850, filed on 19 Apr United States 1995, now abandoned Oceanix Biosciences Corporation, Utility Hanover, MD, United States (U.S. LN.CNT 1033 corporation) INCL INCLM: 514/002.000 US 5837470 981117 US 98-21984 980211 INCLS: 514/008.000; 514/012.000; 530/350.000; 424/084.000 NCL NCLM: 514/002.000 NCLS: 514/008.000; 514/012.000; RLI Division of Ser. No. US 96-766308, filed on 13 Dec 1996 Utility 530/350.000; 424/084.000 LN.CNT 1493 IC [6] INCL INCLM: 435/006.000 ICM: C61K038-16 INCLS: 435/069.100; 435/172.300; ICS: C07K014-065 435/172.200; 435/252.300 EXF 530/350; 514/2; 514/8; 514/12; 424/84

EXF

NCL NCLM: 435/006.000

13 Oct 1992, now abandoned which is a ANSWER 10 OF 292 USPATFULL continuation of Ser. No. US 1998:138709 USPATFULL AN 92-875204, filed on 27 Apr 1992, now Regulated apoptosis. TI Crabtree, Gerald R., Woodside, CA, abandoned which is a ΤN continuation of Ser. No. US 89-428066, United States Schreiber, Stuart L., Cambridge, MA, filed on 26 Oct 1989, now abandoned which is a continuation-in-United States part of Ser. No. US Spencer, David M., Los Altos, CA, 88-264611, filed on 28 Oct 1988, now United States Wandless, Thomas J., Cambridge, MA, abandoned Utility DT United States LN.CNT 3240 Belshaw, Peter, Somerville, MA, United INCLM: 435/007.100 INCL States INCLS: 435/004.000; 435/006.000; President & Fellows of Harvard PΑ 436/501.000; 530/300.000; College, Cambridge, MA, United 530/326.000 States (U.S. corporation) NCLM: 435/007.100 NCLS: 435/004.000; 435/006.000; NCL Board of Trustees of Leland Stanford Jr. University, Stanford, CA, 436/501.000; 530/300.000; United States (U.S. corporation) 530/326.000 US 5834266 981110 US 94-292597 940818 (8) IC [6] ΑI Continuation-in-part of Ser. No. US ICM: G01N033-53 RLI ICS: G01N033-566 94-179143, filed on 7 Jan 435/7.1; 435/4; 435/6; 435/69.1; 1994, now abandoned And Ser. No. US EXF 94-179748, filed on 7 Jan 1994 435/71.1; 436/501; 530/300; 530/326; 530/350; 530/387.1; which is a continuation-in-part of 530/388.1; 530/399; 530/806; 530/808 Ser. No. US 93-92977, filed on 16 Jul 1993, now abandoned which is a continuation-in-part of Ser. ANSWER 12 OF 292 USPATFULL 1998:135173 USPATFULL No. US 93-17931, filed on 12 Feb 1993, AN now abandoned , said Ser.

No. US -179143 which is a Interleukin-8 anti-peptide antibodies тT IN Schraufstatter, Ingrid U., San Diego, continuation-in-part of Ser. No. US CA, United States Cochrane, Charles G., La Jolla, CA, 93-93499, filed on 16 Jul 1993 United States DT Utility LN.CNT 5242 PA The Scripps Research Institute, La Jolla, CA, United States (U.S. INCLM: 435/172.300 INCLS: 435/320.100; 435/325.000; corporation) US 5831032 981103 435/366.000; 536/234.000 PΤ NCLM: 435/172.300 NCLS: 435/320.100; 435/325.000; US 96-643515 960506 (8) ΑI RLI Division of Ser. No. US 94-342348, filed on 21 Nov 1994, now 435/366.000; 536/234.000 abandoned which is a continuation of 161 Ser. No. US 91-755824, filed ICM: C12N015-62 ICS: C12N015-63; C12N015-79; C12N005on 6 Sep 1991, now abandoned which is a continuation-in-part of Ser. No. US 90-581673, filed on 12 Sep EXF 424/93.21; 514/44; 435/69.7; 435/240.2; 435/320.1; 435/23.4; 1990, now abandoned Utility DT 435/23.5; 435/325; 435/366; 435/372.3; LN.CNT 1372 435/172.3; 536/23.4; 536/23.5 INCL INCLM: 530/387.900 CAS INDEXING IS AVAILABLE FOR THIS PATENT. INCLS: 530/388.100; 530/388.230; 530/389.200; 530/326.000; 530/412.000; 530/413.000 ANSWER 11 OF 292 USPATFULL L2 NCLM: 530/387.900 1998:138693 USPATFULL AΝ NCLS: 530/388.100; 530/388.230; TT Method for identifying active domains 530/389.200; 530/326.000; and amino acid residues in polypeptides and hormone variants 530/412.000; 530/413.000 IC [6] Wells, James A., Burlingame, CA, TCM: C07K016-24 United States 560/387.1; 560/388.1; 560/388.25; EXF Cunningham, Brian C., Piedmont, CA, 560/389.2; 560/387.9; 560/326; United States 514/412; 514/413 Genentech, Inc., South San Francisco, CA, United States (U.S. ANSWER 13 OF 292 USPATFULL L2 corporation) US 5834250 981110 AN 1998:135151 USPATFULL PΤ US 97-903398 970630 (8) TΙ Human receptor for interleukin-12 ΑI Continuation of Ser. No. US 95-483039, TN Chua, Anne On, Wayne, NJ, United RLI filed on 6 Jun 1995, now States patented, Pat. No. US 5766854 which is Gubler, Ulrich Andreas, Glen Ridge, a continuation of Ser. No. NJ, United States Hoffmann-La Roche Inc., Nutley, NJ, US 94-190723, filed on 2 Feb 1994, now United States (U.S. patented, Pat. No. US corporation) 5580723 which is a continuation of US 5831007 981103 Ser. No. US 92-960227, filed on PΤ

93-136817, filed on 14 Oct 1993, now US 95-419652 950411 (8) Division of Ser. No. US 94-248532, abandoned RLI filed on 31 May 1994, now DΤ Utility LN.CNT 1993 patented, Pat. No. US 5536657 which is a continuation-in-part of INCL INCLM: 424/144.100 INCLS: 424/143.100; 424/153.100; Ser. No. US 93-94713, filed on 19 Jul 1993, now abandoned 424/154.100; 424/155.100; 424/156.100; 530/388.200; DT Utility LN.CNT 1929 530/388.220; 530/388.230; INCLM: 530/350.000 530/388.240; 435/332.000 INCL INCLS: 530/351.000; 514/002.000; NCL NCLM: 424/144.100 514/008.000 NCLS: 424/143.100; 424/153.100; NCLM: 530/350.000 424/154.100; 424/155.100; NCLS: 530/351.000; 514/002.000; 424/156.100; 530/388.200; 514/008.000 530/388.220; 530/388.230; IC [6] 530/388.240; 435/332.000 ICM: C07K014-715 IC EXF 514/2; 514/8; 530/350; 530/351 ICM: A16K039-395 ICS: A16K035-12; C07K016-18; C12N005-1.2 ANSWER 14 OF 292 USPATFULL 12 AN 1998:135009 USPATFULL EXF 424/141.1; 424/154.1; 424/143.1; ТT Peptides with bactericidal activity 424/140.1; 424/144.1; 424/155.1; 424/156.1; 424/153.1; 530/388.1; and endotoxin neutralizing 530/387.1; 530/388.73; activity for gram negative bacteria and methods for their use 530/388.75; 530/388.2; 530/388.22; 530/388.23; 530/388.24; 435/332 IN Gray, Beulah H., St. Paul, MN, United States Haseman, Judith R., Eagan, MN, United L2 ANSWER 16 OF 292 USPATFULL 1998:134626 USPATFULL States Mayo, Kevin H., Minnetonka, MN, United Regulated transcription of targeted TΙ States genes and other biological Regents of the University of events Minnesota, Minneapolis, MN, United Crabtree, Gerald R., Woodside, CA, States (U.S. corporation) United States PΙ US 5830860 981103 Schreiber, Stuart L., Cambridge, MA, US 96-653632 960524 (8) United States Continuation-in-part of Ser. No. US Spencer, David M., Los Altos, CA, 94-218026, filed on 24 Mar United States 1994 Wandless, Thomas J., Cambridge, MA, DΤ Utility United States LN.CNT 3083 Belshaw, Peter, Cambridge, MA, United States INCLM: 514/012.000 President & Fellows of Harvard INCLS: 514/013.000; 514/014.000; PΑ 514/015.000; 514/021.000; College, Cambridge, MA, United 435/069.700 States (U.S. corporation) NCLM: 514/012.000 Board of Trustees of Leland S. NCLS: 514/013.000; 514/014.000; Stanford, Jr. University, Stanford, 514/015.000; 514/021.000; CA, United States (U.S. corporation) US 5830462 981103 435/069.700 PT [6] ΑI US 95-478386 950607 (8) IC ICM: A61K038-08 RLI Division of Ser. No. US 95-388653, ICS: A61K038-10; A61K038-17 filed on 14 Feb 1995 And a 514/12; 514/13; 514/14; 514/15; continuation-in-part of Ser. No. US 514/21; 435/69.7 94-292597, filed on 18 Aug 1994 which is a continuation-in-part CAS INDEXING IS AVAILABLE FOR THIS PATENT. of Ser. No. US 94-179748, L2 ANSWER 15 OF 292 USPATFULL filed on 7 Jan 1994, now abandoned 1998:134631 USPATFULL which is a continuation-in-part of Ser. No. US 93-92977, filed on 16 ΤI Fas antagonists and uses thereof Lynch, David H., Bainbridge Island, IN Jul 1993, now abandoned which WA, United States is a continuation-in-part of Ser. No. US 93-17931, filed on 12 Feb 1993, now abandoned , said Ser. No. US Alderson, Mark R., Bainbridge Island, WA, United States PA Immunex Corporation, Seattle, WA, -388653 which is a United States (U.S. corporation) continuation-in-part of Ser. No. US US 5830469 981103 94-196043, filed on 11 Feb PΤ US 95-429499 950426 (8) ΑT 1994 which is a continuation-in-part of Ser. No. US -179748 Continuation-in-part of Ser. No. US 94-322805, filed on 13 Oct which is a continuation-in-part of 1994, now patented, Pat. No. US Ser. No. US -92977 which is a 5620889 which is a continuation-in-part of Ser. No. US -17931 continuation-in-part of Ser. No. US 93-159003, filed on 29 Nov DT Utility LN.CNT 4524 1993, now abandoned which is a

INCL INCLM: 424/093.210

continuation-in-part of Ser. No. US

INCLS: 435/172.300; 514/044.000 IN Klein, J. Peter, Vashon, WA, United NCLM: 424/093.210 NCLS: 435/172.300; 514/044.000 NCL States Underiner, Gail E., Brier, WA, United IC [6] ICM: C12N015-63 Kumar, Anil M., Seattle, WA, United ICS: A61K031-70; A61K048-00 States 435/69.1; 435/69.7; 435/240.2; EXE PA Cell Therapeutics, Inc., Seattle, WA, 435/320.1; 435/172.3; 935/34; United States (U.S. 935/36; 935/70; 935/71; 424/93.21; corporation) US 5824677 981020 PΤ US 95-474816 950607 (8) ΑI ANSWER 17 OF 292 USPATFULL RLI Division of Ser. No. US 94-303842, 1998:134612 USPATFULL filed on 8 Sep 1994, now TΙ Compositions and methods for the patented, Pat. No. US 5641783 which is treatment of tumors a continuation-in-part of Vehar, Gordon A., San Carlos, CA, Ser. No. US 93-152650, filed on 12 Nov United States 1993, now patented, Pat. PA Genentech, Inc., South San Francisco, No. US 5801181 And Ser. No. US 93-CA, United States (U.S. 164081, filed on 8 Dec 1993, now corporation) patented, Pat. No. US 5470878 , said US 5830448 981103 Ser. No. US -152650 And US 95-470777 950606 (8) ΑI Ser. No. US -164081 , each Ser. No. Division of Ser. No. US 94-260850, - which is a filed on 16 Jun 1994 continuation-in-part of Ser. No. US Utility 93-40820, filed on 31 Mar LN.CNT 1698 1993, now abandoned Utility INCL INCLM: 424/085.200 LN.CNT 3136 INCLS: 514/002.000; 530/351.000; 530/381.000; 424/085.500; INCL INCLM: 514/222.500 424/085.100 INCLS: 514/223.500; 514/224.500; NCLM: 424/085.200 NCLS: 514/002.000; 530/351.000; NCL 514/226.800; 514/227.500; 514/228.800; 514/229.200; 530/381.000; 424/085.500; 514/230.500; 514/230.800; 424/085.100 514/237.800; 514/248.000; TC 514/249.000; 514/255.000; ICM: A61K045-05 514/258.000; 514/274.000; ICS: A61K038-00 514/301.000; 514/303.000; EXF 514/2; 530/351; 530/381; 424/85.2; 514/311.000; 514/351.000; 424/85.5; 424/85.1 514/360.000; 514/361.000; 514/362.000; 514/363.000; ANSWER 18 OF 292 USPATFULL L2 514/364.000; 514/365.000; AN 1998:128378 USPATFULL 514/367.000; 514/372.000; Human stromelysin-1 promoter 514/373.000; 514/374.000; IN Borden, Paula Ann, Palo Alto, CA, 514/375.000; 514/376.000; 514/378.000; 514/379.000; United States Heller, Renu Anand, Stanford, CA, 514/380.000; 514/387.000; United States 514/395.000; 514/415.000; PA Syntex (U.S.A.) Inc., Palo Alto, CA, 514/418.000; 514/424.000; United States (U.S. 514/425.000; 514/433.000; corporation) 514/452.000; 514/432.000; US 5824794 981020 514/438.000; 346/113.000; US 94-362706 941223 (8) AΙ 346/114.000; 346/164.000; DТ Utility 346/300.000; 549/014.000; LN.CNT 812 549/050.000; 549/075.000; INCL INCLM: 536/024.100 549/367.000; 549/368.000; INCLS: 435/172.300; 435/320.100; 544/002.000; 544/003.000; 435/325.000; 435/366.000; 544/005.000; 544/008.000; 435/252.300; 536/023.500 544/053.000; 544/063.000; NCLM: 536/024.100 544/065.000; 544/066.000; NCLS: 435/252.300; 435/320.100; 544/067.000; 544/090.000; 435/325.000; 435/366.000; 544/091.000; 544/127.000; 536/023.500 544/128.000; 544/162.000; TC 161 544/215.000; 544/219.000; ICM: C07H021-04 544/229.000; 544/235.000; ICS: C12N005-16; C12N015-12; C12N015-544/237.000; 544/255.000; 85 544/278.000; 544/311.000; 514/44; 536/23.1; 536/24.1; 536/23.5; 544/353.000; 544/385.000; 435/320.1; 435/240.2; 435/6; 548/123.000; 548/125.000; 435/252.3; 435/366; 435/172.3; 548/131.000; 548/134.000; 435/325; 424/93.21 548/143.000; 548/146.000; 548/153.000; 548/174.000; ANSWER 19 OF 292 USPATFULL 548/207.000; 548/214.000; ΑN 1998:128265 USPATFULL 548/215.000; 548/217.000; Substituted amino alcohol compounds 548/221.000; 548/228.000; 548/229.000; 548/237.000;

548/240.000; 548/241.000;	514/380; 514/387; 514/395; 514/415;
548/243.000; 548/247.000;	514/418; 514/424; 514/425;
548/267.200; 548/303.700;	514/433; 514/452; 544/2; 544/3; 544/5;
548/307.100; 548/453.000; 548/486.000; 548/543.000;	544/8; 544/53; 544/63; 544/65; 544/66; 544/67; 544/90;
548/546.000	544/91; 544/127; 544/128; 544/162;
NCL NCLM: 514/222.500	544/215; 544/219; 544/229; 544/235;
NCLS: 514/223.500; 514/224.500;	544/237; 544/255; 544/278;
514/226.800; 514/227.500;	544/311; 544/353; 544/385; 546/113;
514/228.800; 514/229.200;	546/114; 546/164; 546/300;
514/230.500; 514/230.800;	548/123; 548/125; 548/131; 548/134;
514/237.800; 514/248.000;	548/145; 548/146; 548/153;
514/249.000; 514/255.000;	548/174; 548/207; 548/214; 548/215;
514/258.000; 514/274.000;	548/217; 548/221; 548/228;
514/301.000; 514/303.000;	548/229; 548/237; 548/240; 548/241;
514/311.000; 514/351.000;	548/243; 548/247; 548/267.2;
514/360.000; 514/361.000;	548/303.7; 548/307.1; 548/453;
514/362.000; 514/363.000; 514/364.000; 514/365.000;	548/486; 548/543; 548/546 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
514/367.000; 514/372.000;	CAS INDEXING IS AVAILABLE FOR INTS PATENT.
514/373.000; 514/374.000;	L2 ANSWER 20 OF 292 USPATFULL
514/375.000; 514/376.000;	AN 1998:128224 USPATFULL
514/378.000; 514/379.000;	TI Antiproliferative protein from
514/380.000; 514/387.000;	Bacillus thuringiensis var.
514/395.000; 514/415.000;	thuringiensis
514/418.000; 514/424.000;	IN Aggarwal, Bharat B., Houston, TX,
514/425.000; 514/432.000;	United States
514/433.000; 514/438.000;	Rodriguez-Padilla, Cristina,
514/452.000; 544/002.000;	Monterrey, Mexico
544/003.000; 544/005.000;	PA Research Development Corporation,
544/008.000; 544/053.000;	Carson City, NV, United States
544/063.000; 544/065.000;	(U.S. corporation)
544/066.000; 544/067.000;	Universidad Autonoma de Nuevo Leon,
544/090.000; 544/091.000;	Nuevo Leon, Mexico (non-U.S.
544/127.000; 544/128.000; 544/162.000; 544/215.000;	corporation) PI US 5824636 981020
544/219.000; 544/229.000;	PI US 5824636 981020 AI US 96-743553 961104 (8)
544/235.000; 544/237.000;	RLI Continuation of Ser. No. US 95~454636,
544/255.000; 544/278.000;	filed on 31 May 1995, now
544/311.000; 544/353.000;	abandoned
544/385.000; 546/113.000;	DT Utility
546/114.000; 546/164.000;	LN.CNT 823
546/300.000; 548/123.000;	INCL INCLM: 514/002.000
548/125.000; 548/131.000;	INCLS: 530/350.000
548/134.000; 548/143.000;	NCL NCLM: 514/002.000
548/146.000; 548/153.000;	NCLS: 530/350.000
548/174.000; 548/207.000;	IC [6]
548/214.000; 548/215.000;	ICM: A61K039-07
548/217.000; 548/221.000; 548/228.000; 548/229.000;	ICS: A61K038-16; C07K014-32 EXF 530/350; 514/2; 424/93.461
548/237.000; 548/240.000;	
548/241.000; 548/243.000;	CAS INDEXING IS AVAILABLE FOR THIS PATENT.
548/247.000; 548/267.200;	=> e greene john/au
548/303.700; 548/307.100;	y =
548/453.000; 548/486.000;	E1 1 GREENE JOEL C/AU
548/543.000; 548/546.000;	E2 1 GREENE JOHATHAN W/AU
549/014.000; 549/050.000;	E3 2> GREENE JOHN/AU
549/075.000; 549/367.000;	E4 3 GREENE JOHN D/AU
549/368.000	E5 1 GREENE JOHN F/AU
IC [6]	E6 1 GREENE JOHN L/AU
ICM: A61K031-385	E7 4 GREENE JOHN M/AU
ICS: A61K031-445; A61K031-47; A61K031-	E8 2 GREENE JOHN P/AU
505 EXF 549/75; 549/50; 549/14; 549/367;	E9 1 GREENE JONATHAN/AU
549/368; 514/432; 514/438;	E10 1 GREENE JONATHAN A/AU
5147222.5: 5147223 5: 5147224 5:	E11 11 GREENE JONATHAN W/AU E12 1 GREENE JOSEPH F/AU
514/222.5; 514/223.5; 514/224.5; 514/226.8; 514/227.5; 514/228.8;	E11 11 GREENE JONATHAN W/AU E12 1 GREENE JOSEPH E/AU
514/226.8; 514/227.5; 514/228.8;	E12 1 GREENE JOSEPH E/AU
	·
514/226.8; 514/227.5; 514/228.8; 514/229.2; 514/230.5; 514/230.8;	E12 1 GREENE JOSEPH E/AU
514/226.8; 514/227.5; 514/228.8; 514/229.2; 514/230.5; 514/230.8; 514/237.8; 514/248; 514/249;	E12 1 GREENE JOSEPH E/AU => s e7 and l1
514/226.8; 514/227.5; 514/228.8; 514/229.2; 514/230.5; 514/230.8; 514/237.8; 514/248; 514/249; 514/255; 514/258; 514/274; 514/301;	E12 1 GREENE JOSEPH E/AU => s e7 and l1 4 "GREENE JOHN M"/AU
514/226.8; 514/227.5; 514/228.8; 514/229.2; 514/230.5; 514/230.8; 514/237.8; 514/248; 514/249; 514/255; 514/258; 514/274; 514/301; 514/303; 514/311; 514/351; 514/360; 514/361; 514/362; 514/363; 514/364; 514/365; 514/367;	E12 1 GREENE JOSEPH E/AU => s e7 and l1 4 "GREENE JOHN M"/AU
514/226.8; 514/227.5; 514/228.8; 514/229.2; 514/230.5; 514/230.8; 514/237.8; 514/248; 514/249; 514/255; 514/258; 514/274; 514/301; 514/303; 514/311; 514/351; 514/360; 514/361; 514/362; 514/363; 514/364; 514/365; 514/367; 514/372; 514/373; 514/374; 514/375;	E12 1 GREENE JOSEPH E/AU => s e7 and 11 4 "GREENE JOHN M"/AU L3 0 "GREENE JOHN M"/AU AND L1 => e greene j/au
514/226.8; 514/227.5; 514/228.8; 514/229.2; 514/230.5; 514/230.8; 514/237.8; 514/248; 514/249; 514/255; 514/258; 514/274; 514/301; 514/303; 514/311; 514/351; 514/360; 514/361; 514/362; 514/363; 514/364; 514/365; 514/367;	E12 1 GREENE JOSEPH E/AU => s e7 and l1 4 "GREENE JOHN M"/AU L3 0 "GREENE JOHN M"/AU AND L1

```
1
                  GREENE IRWIN R/AU
             0 --> GREENE J/AU
E3
                   GREENE J JERROLD/AU
E4
             1
                   GREENE JACK C/AU
Ε6
                   GREENE JACK E/AU
E7
                 GREENE JACK T/AU
                   GREENE JAMES A/AU
GREENE JAMES ALBERT/AU
E8
             3
             1
E9
                   GREENE JAMES B/AU
E10
             1
                   GREENE JAMES D/AU
E11
                   GREENE JAMES E/AU
E12
             1
=> e greene jo/au
                   GREENE JERRY/AU
GREENE JIMMY D/AU
             1
             1
ΕЗ
             0 --> GREENE JO/AU
             1 GREENE JOE A/AU
E4
                   GREENE JOEL C/AU
E5
             1
                   GREENE JOHATHAN W/AU
E7
                   GREENE JOHN/AU
                   GREENE JOHN D/AU
E8
                   GREENE JOHN F/AU
E9
             1
                   GREENE JOHN L/AU
E10
             1
                   GREENE JOHN M/AU
E11
                   GREENE JOHN P/AU
E12
```

=> logoff

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF LOGOFF? (Y)/N/HOLD: γ

COST IN U.S. DOLLARS SINCE FILE TOTAL

ENTRY SESSION FULL ESTIMATED COST 37.55 37.70

STN INTERNATIONAL LOGOFF AT 00:30:26 ON 23 NOV 1998